Another example is MET, a well-known drug target in non-small-cell lung cancer, both protein overexpression and gene amplification of MET indicated a better response of patients to MET inhibitor treatment and worse prognosis [35–37]. The gene discussed is MET; the disease is non-small cell lung carcinoma.